Finlepsin Retard

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Finlepsin retard: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. In case of impaired renal function
12. For violations of liver function
13. Use in the elderly
14. Drug interactions
15. Analogs
16. Terms and conditions of storage
17. Terms of dispensing from pharmacies
18. Reviews
19. Price in pharmacies

Latin name: Finlepsin retard

ATX code: N03AF01

Active ingredient: carbamazepine (carbamazepine)

Producer: Teva Operations Poland (Poland), Menarini-von Heiden GmbH (Germany)

Description and photo update: 2018-21-11

Prices in pharmacies: from 173 rubles.

Buy

Finlepsin retard extended-release tablets

Finlepsin retard is an anticonvulsant drug that has antiepileptic, analgesic, antipsychotic activity.

Release form and composition

Finlepsin retard is available in the form of prolonged-release tablets: from white with a yellow tint to white, flat, rounded, the edges of the tablets are beveled, a cruciform dividing line is applied on each side, 4 notches on the side surface (10 pcs. In blisters, in a cardboard pack of 3, 4 or 5 blisters).

1 tablet contains:

active substance: carbamazepine - 200 or 400 mg;
auxiliary components: triacetin, copolymer Eudragit RS30D [methyl methacrylate, ethyl acrylate and trimethylammonioethyl methacrylate (1: 2: 0.1)], copolymer Eudragit L30D-55 (ethyl acrylate, methacrylic acid), crospovidone, silicon dioxide colloidal microcrystalline, cellulose …

Pharmacological properties

Pharmacodynamics

Carbamazepine, the active substance of Finlepsin retard, is a dibenzazepine derivative. Providing antiepileptic action, it exhibits antipsychotic, antidepressant and antidiuretic activity, in patients with neuralgia it provides an analgesic effect.

The mechanism of action of carbamazepine is due to the blockade of voltage-dependent sodium channels, which causes stabilization of the membrane of overexcited neurons, inhibition of the appearance of serial discharges of neurons and a decrease in synaptic impulse conduction. Prevents re-formation of sodium-dependent action potentials in depolarized neurons. The likelihood of developing an epileptic seizure is reduced due to an increase in the seizure threshold caused by a decrease in the release of monosodium glutamate, an increase in the transport of potassium ions, and the modulation of voltage-gated calcium channels.

The use of carbamazepine is effective in the treatment of the following types of epilepsy: simple and complex partial (focal) epileptic seizures, with or without secondary generalization, generalized tonic-clonic epileptic seizures, and a combination of these two types of seizures. Finlepsin retard is ineffective for minor seizures of epilepsy, absences, myoclonic seizures.

In patients with epilepsy, there is a positive effect of Finlepsin retard on the symptoms of anxiety and depression, especially in children and adolescents, a decrease in the incidence of aggressiveness and irritability. The degree of effect on psychomotor performance and cognitive function depends on the dose of carbamazepine.

The period before the onset of the anticonvulsant effect can range from several hours to several days.

With trigeminal neuralgia, it often prevents pain attacks, the weakening of the existing pain syndrome can occur within 1 / 3–3 days.

With alcohol withdrawal syndrome, it helps to increase the reduced threshold of convulsive readiness, to reduce the severity of its clinical signs (including hyperexcitability, tremor, gait disturbances).

In psychotic (manic) disorders, the therapeutic effect is achieved after 7-10 days.

The prolonged action of the tablets maintains a more stable concentration of carbamazepine in the blood against the background of the use of a daily dose divided into 1-2 doses.

Pharmacokinetics

After taking the pill, there is a slow but almost complete absorption of carbamazepine from the gastrointestinal tract. Food intake does not significantly affect the rate and degree of its absorption.

The maximum concentration (Cmax) of the active substance in the blood plasma is reached 32 hours after a single dose. The average Cmax of unchanged carbamazepine when taking Finlepsin retard 400 mg is approximately 0.0025 mg / ml.

Css (equilibrium plasma concentration) is achieved after 7-14 days of regular administration of the drug. The rate of achievement of Css is influenced by the individual characteristics of metabolism: the patient's condition, the dose and duration of drug administration, autoinduction of liver enzyme systems, heteroinduction by other means of concomitant therapy. In the therapeutic range, the Css value can fluctuate in most patients from 0.004 to 0.012 mg / ml (17-50 µmol / L). The pharmacologically active metabolite of carbamazepine is carbamazepine-10,11-epoxide, its concentration is approximately 30% of the level of carbamazepine.

Plasma protein binding: adults - 70–80%, children - 55–59%.

The estimated Vd (volume of distribution) is 0.8-1.9 L / kg. The concentration level of the active substance in saliva and cerebrospinal fluid is 20-30% of the dose taken, it corresponds to the amount of carbamazepine not bound to plasma proteins.

Carbamazepine crosses the placental barrier, its concentration in breast milk reaches 60% of its total level in blood plasma.

In the liver, it is metabolized by the epoxy pathway (mainly), with the formation of an active metabolite - carbamazepine-10,11-epoxide - and an inactive compound with glucuronic acid. The biotransformation of carbamazepine into carbamazepine-10,11-epoxide is provided by the isoenzyme CYP3A4. The metabolite 9-hydroxy-methyl-10-carbamoylacridane, formed as a result of metabolic reactions, has little pharmacological activity. Carbamazepine tends to induce its own metabolism.

After oral administration of a single dose, T1 / 2 (half-life) is 60 to 100 hours. Autoinduction of liver enzyme systems during prolonged therapy leads to a decrease in T1 / 2.

72% of the dose taken is excreted through the kidneys (of which about 2% unchanged and about 1% in the form of an active metabolite), through the intestines - 28%.

There is no information confirming the change in the pharmacokinetics of carbamazepine in elderly patients.

Indications for use

primary generalized (except absences) and secondary generalized epileptic seizures;
simple and complex types of seizures in the partial form of epilepsy;
epileptiform seizures in multiple sclerosis;
paroxysmal paresthesias and attacks of pain;
tonic convulsions;
idiopathic glossopharyngeal neuralgia;
trigeminal neuralgia;
spasms of the facial muscles with trigeminal neuralgia;
paroxysmal dysarthria and ataxia;
pain with lesions of peripheral nerves that have arisen against the background of diabetes mellitus;
pain syndrome in diabetic neuropathy;
alcohol withdrawal syndrome, accompanied by increased excitability, anxiety, convulsions, sleep disturbances;
psychoses, affective and schizoaffective disorders, functional disorders of the limbic system.

Contraindications

AV (atrioventricular) block;
acute intermittent porphyria (including history);
disorders of bone marrow hematopoiesis (leukopenia, anemia);
combination with monoamine oxidase (MAO) inhibitors and lithium preparations;
age up to 6 years;
hypersensitivity to tricyclic antidepressants;
individual intolerance to the components of the drug.

Finlepsin retard should be prescribed with caution in case of decompensated chronic heart failure, impaired renal and / or liver function, prostatic hyperplasia, increased intraocular pressure, chronic alcoholism, hyponatremia of dilution (hypothyroidism, antidiuretic hormone hypersecretion syndrome, combination of adrenal cortex insufficiency, hypopharynx) sedatives and hypnotics, treatment of elderly patients, in case of suppression of bone marrow hematopoiesis when taking medications (in history), during pregnancy and lactation.

Instructions for the use of Finlepsin retard: method and dosage

Finlepsin retard tablets 200 mg or 400 mg are taken orally during or after meals and washed down with a sufficient amount of water, juice or other liquid.

If necessary, the preliminary dissolution of the dose of the drug in the liquid is allowed, while its pharmacological property is not violated.

The daily dose is divided into 1–2 doses. The maximum daily dose is 1.6 g.

Recommended daily dosage:

epilepsy treatment. Adults: the initial dose (once, in the evening) is 0.2–0.4 g, the dose should be gradually increased until the dose that provides the optimal therapeutic effect in the patient is achieved. The maintenance dose range is 0.8–1.2 g. It is divided into 2 doses: in the morning - 0.2–0.6 g, in the evening - 0.4–0.6 g. Children: initial dose for children 6–15 years (once, in the evening) - 0.2 g, the dose is gradually increased (0.1 g per day) until the optimal effect is achieved. The maintenance dose for children 6-10 years old is 0.4-0.6 g, it is divided into 2 doses in the following proportion: in the morning - 0.2 g each and in the evening - 0.2-0.4 g each. Maintenance dose for children aged 11-15 years is 0.6-1 g: in the morning - 0.2-0.4 g, in the evening - 0.4-0.6 g. The duration of therapy depends on the clinical condition of the patient and the individual tolerance of the drug …It is preferable to prescribe Finlepsin retard as monotherapy. The introduction of the drug into the composition of antiepileptic therapy already underway should be carried out gradually, adjusting the dose of concomitant drugs if necessary. If the next dose is missed, it can be taken if this does not correspond to the simultaneous reception of a double dose of the drug. The doctor makes the decision on the transfer of the patient to treatment with Finlepsin retard, the duration of use or discontinuation of drug therapy individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;The introduction of the drug into the composition of antiepileptic therapy already underway should be carried out gradually, if necessary, adjusting the dose of concomitant drugs. If the next dose is missed, it can be taken if this does not correspond to the simultaneous reception of a double dose of the drug. The doctor makes the decision on the transfer of the patient to treatment with Finlepsin retard, the duration of use or discontinuation of drug therapy individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;The introduction of the drug into the composition of antiepileptic therapy already underway should be carried out gradually, adjusting the dose of concomitant drugs if necessary. If the next dose is missed, it can be taken if this does not correspond to the simultaneous reception of a double dose of the drug. The doctor makes the decision on the transfer of the patient to treatment with Finlepsin retard, the duration of use or discontinuation of drug therapy individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;adjusting the dose of concomitant drugs if necessary. If the next dose is missed, it can be taken if this does not correspond to the simultaneous reception of a double dose of the drug. The doctor makes the decision on the transfer of the patient to treatment with Finlepsin retard, the duration of use or discontinuation of drug therapy individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;adjusting the dose of concomitant drugs if necessary. If the next dose is missed, it can be taken if this does not correspond to the simultaneous reception of a double dose of the drug. The doctor makes the decision on the transfer of the patient to treatment with Finlepsin retard, the duration of use or discontinuation of drug therapy individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;the duration of use or cessation of drug therapy, the doctor takes individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;the duration of use or cessation of drug therapy, the doctor takes individually. It is possible to reduce the dose or to cancel the drug only if there are no seizures for 2-3 years. Treatment is stopped within 1-2 years, gradually reducing the dose under the control of electroencephalography. In children, with a decrease in the daily dose, it is necessary to take into account the age-related increase in body weight;
epileptiform seizures in multiple sclerosis: 0.2–0.4 g;
trigeminal neuralgia and idiopathic glossopharyngeal neuralgia: the initial dose is 0.2–0.4 g, its increase is shown until the pain disappears completely. The maximum daily dose is 0.8 g. The maintenance dose is usually 0.4 g. The initial dose in elderly patients or with individual sensitivity to the action of carbamazepine should be 0.2 g once a day;
pain syndrome in diabetic neuropathy: 0.2 g in the morning and 0.4 g in the evening. In exceptional cases, to achieve a therapeutic effect, the appointment of Finlepsin retard in the morning and in the evening at a dose of 0.6 g is shown;
treatment of alcohol withdrawal syndrome in a hospital setting: usually - 0.6 g (0.2 g in the morning and 0.4 g in the evening), in severe cases - 1.2 g for the first few days. The drug can be combined with other drugs used to treat alcohol withdrawal symptoms. You cannot combine Finlepsin retard with sedatives and hypnotics. Careful observation of the mental state of the patient should be ensured. Treatment should be accompanied by regular monitoring of the level of carbamazepine in blood plasma;
psychosis (treatment and prevention): initial and maintenance dose - 0.2-0.4 g. Maximum daily dose - 0.8 g.

Side effects

from the immune system: often - urticaria; sometimes - angioedema, various combinations of manifestations of multi-organ hypersensitivity reactions of delayed type (fever, skin rashes, vasculitis, erythema nodosum, erythroderma, lymphadenopathy, signs of lymphoma, arthralgia, leukopenia, eosinophilia, hepatosplenomegaly, changes in lung function, pancreas, kidney, myocardium and / or colon, aseptic meningitis with myoclonus and peripheral eosinophilia, allergic pneumonitis (eosinophilic pneumonia), anaphylactoid reaction; rarely - pruritus, lupus-like syndrome, photosensitivity, exudative erythema multiforme, Stevens' syndrome (including erythema syndrome) toxic epidermal necrolysis);
from the nervous system: often - drowsiness, dizziness, general weakness, headache, paresis of accommodation, ataxia; sometimes - abnormal involuntary movements (including tics, dystonia, tremor, fluttering tremor), nystagmus; rarely - decreased appetite, visual or auditory hallucinations, anxiety, disorientation, aggressive behavior, orofacial dyskinesia, psychomotor agitation, depression, activation of psychosis, eye movement disorders, speech disorders (including dysarthria, slurred speech), peripheral neuritis, choreoathetoid disorders, paresthesias muscle weakness, paresis;
from the hematopoietic system: often - thrombocytopenia, leukopenia, eosinophilia; rarely - folic acid deficiency, leukocytosis, lymphadenopathy, agranulocytosis, true erythrocytic aplasia, aplastic anemia, megaloblastic anemia, reticulocytosis, acute intermittent porphyria, splenomegaly, hemolytic anemia;
on the part of the cardiovascular system: rarely - violation of blood pressure, bradycardia, arrhythmias, intracardiac conduction disturbances, AV blockade with fainting, exacerbation or development of chronic heart failure, collapse, development or increased frequency of angina attacks, exacerbation of ischemic heart disease, thromboembolic syndrome, thrombophlebitis;
from the digestive system: often - dry mouth, nausea, vomiting, increased activity of gamma-glutamyl transferase, increased activity of alkaline phosphatase; sometimes - abdominal pain, diarrhea or constipation, increased activity of liver enzymes; rarely - stomatitis, glossitis, gingivitis, pancreatitis, jaundice, hepatitis (granulomatous, cholestatic, parenchymal), liver failure;
from the metabolic and endocrine system: often - fluid retention, edema, weight gain, hyponatremia; rarely - dilutional hyponatremia (accompanied by vomiting, headache, neurological disorders, lethargy, disorientation), increased prolactin levels, galactorrhea, gynecomastia, a decrease in the level of levothyroxine sodium (L-thyroxine), an increase in the concentration of thyroid-stimulating hormone (usually without clinical manifestations), hirsutism, violation of calcium-phosphorus metabolism in bone tissue (osteomalacia, enlarged lymph nodes, hypertriglyceridemia, hypercholesterolemia, including high-density lipoprotein cholesterol);
from the musculoskeletal system: rarely - convulsions, arthralgia, myalgia;
from the genitourinary system: rarely - a decrease in potency, frequent urination, interstitial nephritis, albuminuria, hematuria, oliguria, increased urea concentration (azotemia), other kidney pathologies, renal failure, urinary retention;
on the part of the senses: rarely - a violation of taste, increased intraocular pressure, clouding of the lens, conjunctivitis, hearing impairment (including tinnitus, change in the perception of pitch, hyperacusis, hypoacusia);
dermatological reactions: sweating, acne, skin pigmentation disorders, alopecia, purpura.

Overdose

Symptoms: nausea, vomiting, delayed evacuation of stomach contents, decreased motility of the colon; depression of the function of the central nervous system, drowsiness, agitation, disorientation, hallucinations, coma; hypothermia, blurred vision, slurred speech, nystagmus, dysarthria, ataxia, dyskinesia, hyperreflexia alternating with hyporeflexia, psychomotor disorders, convulsions, myoclonus, mydriasis; lowering (less often - increasing) blood pressure, tachycardia, fainting, disturbances of intraventricular conduction with an expansion of the QRS complex, cardiac arrest, respiratory depression, pulmonary edema, fluid retention in the body, rare urination, oliguria or anuria. Changes in laboratory parameters: decrease or increase in the number of leukocytes in the blood, hyponatremia, possibly metabolic acidosis, increase in the muscle fraction of creatine phosphokinase, hyperglycemia,glucosuria.

Treatment: there is no specific antidote, therefore, it is necessary to prescribe symptomatic maintenance therapy in the intensive care unit - immediate gastric lavage, prescription of activated charcoal, determination of the concentration of carbamazepine in blood plasma (in order to confirm drug poisoning and assess the degree of overdose); monitoring of heart function, body temperature, kidney and bladder function, corneal reflexes, correction of electrolyte disorders. Delayed absorption with delayed evacuation of gastric contents can cause re-manifestation of symptoms of intoxication.

The use of hemodialysis, peritoneal dialysis or forced diuresis for the purpose of detoxification is ineffective. Dialysis is indicated for patients with renal insufficiency. In children, when treating an overdose, it is possible to use blood transfusion.

special instructions

The degree of influence of carbamazepine on the development of neuroleptic malignant syndrome, especially when combined with antipsychotics, has not been established.

The development of side effects from the central nervous system can be caused by a relative overdose of the drug or significant fluctuations in the concentration of carbamazepine in the blood plasma.

The appointment of Finlepsin retard can only be made on condition that the doctor regularly monitors the patient's condition.

While using the drug, there is a risk of suicidal attempts or intentions, the mechanism of which is not known. Patients, their relatives and service personnel should be informed about this and that if symptoms of suicidal behavior occur, they should immediately seek medical attention.

To select an individual initial and maintenance dose that provides an optimal effect, it is advisable to determine the level of carbamazepine in the blood plasma, especially when Finlepsin retard is prescribed as part of a combination therapy, since with accelerated metabolism caused by the induction of microsomal liver enzymes or the interaction of simultaneously used drugs, the patient may a dose that is significantly different from the recommended dose is required.

A sudden cancellation of Finlepsin retard can cause an epileptic seizure, therefore, if it is necessary to abruptly interrupt therapy, the patient should be switched to another antiepileptic drug under the cover of intravenous (IV) or rectal administration of diazepam, phenytoin (IV) or another agent indicated in such cases.

Alcohol consumption is contraindicated while using the drug.

The transition to treatment with carbamazepine is made by gradually reducing the dose of the previously taken antiepileptic drug.

Women of reproductive age should not use hormonal oral contraceptives because they do not provide reliable contraception and can cause bleeding between menstrual periods.

Taking pills is required to be accompanied by regular monitoring of liver function indicators, especially in the elderly and patients with a history of liver disease. With the development of severe liver disease, Finlepsin retard must be canceled immediately.

When prescribing the drug for the first 4 weeks of treatment weekly and then once every 4 weeks, it is necessary to conduct a blood test to determine the indicators of the number of platelets, reticulocytes, the level of iron, urea and the concentration of electrolytes in the blood serum. In addition, a general analysis of urine, electroencephalography is required.

Treatment should be discontinued in case of leukopenia with clinical symptoms of infectious pathology or progressive leukopenia.

The appearance of mild skin reactions in the form of an isolated macular or macular-papular rash usually does not require the cancellation of Finlepsin retard, the symptoms disappear on their own, including after lowering the dose of the drug. During this period, the patient needs medical supervision. If you experience a hypersensitivity reaction, symptoms of Stevens-Johnson syndrome or Lyell's syndrome, the pill should be stopped.

The doctor should inform the patient about the possible development of toxic reactions, the early signs of which may be fever, rash, sore throat, ulceration of the oral mucosa, the occurrence of hematomas, hemorrhages or purpura. For the timely diagnosis of these symptoms, you must consult a doctor.

Before starting treatment, the patient is recommended to undergo an ophthalmological examination, including measurement of intraocular pressure and examination of the fundus. With increased intraocular pressure, it must be constantly monitored while taking carbamazepine.

In severe diseases of the cardiovascular system, liver and (or) kidney damage, as well as elderly people, it is recommended to use Finlepsin retard in reduced doses.

Regular determination of the plasma level of carbamazepine is advisable if there is a suspicion of a violation of its absorption, to control the regularity of the drug intake by the patient, with a sharp increase in the frequency of attacks, during pregnancy, when treating children, when signs of toxic reactions appear.

Application during pregnancy and lactation

Care should be taken when prescribing Finlepsin retard during gestation and lactation.

The use of carbamazepine in women of reproductive age is preferable to prescribe in the minimum effective dose as monotherapy, since against the background of combined antiepileptic treatment, the incidence of congenital pathologies in newborns is higher.

In the first trimester of pregnancy, the risk of intrauterine developmental disorders when taking Finlepsin retard is especially high, therefore, when confirming conception, it is necessary to assess the relationship between the benefits of therapy for the mother and the risk of possible diseases and fetal malformations, including non-closure of the vertebral arches.

Carbamazepine increases folic acid deficiency, so it should be started when planning pregnancy and continued throughout the gestation period. This will reduce the risk of birth defects in children.

To prevent hemorrhagic complications in the fetus, it is necessary to take vitamin K in the last weeks of pregnancy, and after childbirth it is recommended to prescribe it to newborns.

Finlepsin retard passes into breast milk and can cause severe drowsiness in the child, skin rashes of allergic etiology and other negative reactions. Therefore, in the context of ongoing therapy, the safety of breastfeeding should be assessed and a decision should be made about its appropriateness.

Pediatric use

The appointment of Finlepsin retard is contraindicated in children under 6 years of age.

With impaired renal function

Caution should be exercised during the period of treatment with the drug in patients with impaired renal function.

For violations of liver function

Care must be taken during the period of treatment with the drug in patients with impaired liver function.

Use in the elderly

According to the instructions, Finlepsin retard should be used with caution to treat elderly patients.

The initial dose of carbamazepine should not exceed 0.2 g once a day.

Drug interactions

With the simultaneous use of Finlepsin retard:

inhibitors of the isoenzyme CYP3A4: can increase the level of carbamazepine in the blood plasma and the development of unwanted reactions;
inducers of the isoenzyme CYP3A4: can cause an acceleration of the metabolism of carbamazepine and a decrease in its concentration in blood plasma and a therapeutic effect. At the same time, when they are canceled, the concentration of carbamazepine increases, since the rate of its biotransformation decreases;
MAO inhibitors: can cause the development of hyperthermic and hypertensive crises, seizures, lead to death, therefore, the interval between their intake should be at least two weeks;
lithium preparations: cause an increase in the neurotoxic effect of each of the drugs;
verapamil, nicotinamide, diltiazem, desipramine, felodipine, danazol, dextropropoxyphene, acetazolamide, viloxazine, cimetidine, fluoxetine, fluvoxamine, macrolides - clarithromycin, josamycin, troleandomycin, erythromuconazole, and lactonidazole, propoxyphene, ritonavir and other protease inhibitors for the treatment of human immunodeficiency virus infection: increase the concentration of carbamazepine in the blood plasma, therefore, monitoring of the plasma level of carbamazepine or correction of its dosage regimen is required;
valproic acid, primidone: displacing carbamazepine from its connection with plasma proteins, can increase the concentration of a pharmacologically active metabolite (carbamazepine-10,11-epoxide) and the development of severe side effects;
phenobarbital, primidone, phenytoin, metsuximide, fensuximide, rifampicin, theophylline, cisplatin, doxorubicin, clonazepam, valpromide, oxcarbazepine, valproic acid, preparations containing St. John's wort: may reduce the concentration of the drug;
felbamate: causes a decrease in the level of carbamazepine and an increase in the content of carbamazepine-10,11-epoxide in the blood plasma, a simultaneous decrease in the concentration in the serum and the effect of felbamate is possible;
isotretinoin: alters the bioavailability and / or clearance of carbamazepine, carbamazepine-10,11-epoxide;
phenothiazine, pimozide, thioxanthenes (chlorprothixene), molindone, haloperidol, maprotiline, clozapine, tricyclic antidepressants: weaken the anticonvulsant effect of the drug, increasing the inhibitory effect on the central nervous system;
clobazam, clonazepam, prednisolone, digoxin, ethosuximide, prednisolone, valproic acid, prednisolone, alprazolam, dexamethasone, cyclosporin, methadone, doxycycline, haloperidol, theophylline, oral contraceptives, phenylephrine (or estrogen-antagonist)), topiramate, lamotrigine, tricyclic antidepressants (amitriptyline, imipramine, clomipramine, nortriptyline), clozapine, oxcarbazepine, tiagabine, protease inhibitors - indinavir, ritonavir and saquinavir, levothyroxine, calcium channel blockers, tradazapodine praziquantel, risperidone, ziprasidone, itraconazole: lower their plasma level and their therapeutic effect;
tetracyclines: may weaken the therapeutic effect of carbamazepine;
myelotoxic drugs: cause an increase in the hematotoxic manifestations of carbamazepine;
indirect anticoagulants, hormonal contraceptives, folic acid, praziquantel: speed up your metabolism;
paracetamol: speeds up its metabolism, which leads to an increased risk of toxic effects on the liver and a decrease in the therapeutic effectiveness of paracetamol;
hydrochlorothiazide, furosemide (diuretics): contribute to the development of hyponatremia with clinical manifestations;
pancuronium and other non-depolarizing muscle relaxants: weaken their effect, a correction of their dose is required;
thyroid hormones: can enhance elimination;
enflurane, halothane, fluorothane (anesthetics): accelerate their metabolism, increasing the risk of hepatotoxic effects;
methoxyflurane: increases the formation of its nephrotoxic metabolites;
isoniazid: enhances its hepatotoxic effect;
ethanol: worsens its effect.

Analogs

Finlepsin retard analogs are Finlepsin, Carbamazepin, Apo-Carbamazepine, Carbalepsin retard, Zagretol, Zeptol, Mazepin, Tegretol, Stazepin, Storilat.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 30 ° C.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Finlepsin retard

Reviews about Finlepsin retard are mostly positive. They indicate the effective action of the drug in the treatment of epilepsy, inflammation of the trigeminal nerve, and attacks of depression. Patients with epilepsy note that regular pills can prevent seizures (there are practically no seizures) and stabilize mood. When treating inflammation of the trigeminal nerve, it perfectly relieves pain syndrome, helps to survive severe exacerbations of back pain.

The advantages of tablets include convenience in breaking them and an affordable price.

In some patients, Finlepsin retard causes undesirable effects (fluid retention in the body, effects on the heart, hearing impairment, compression of the temples, etc.), sometimes requiring its cancellation.

Patients who have extensive experience in using Finlepsin retard report frequent cases of buying counterfeit pill packs. To the disadvantages of the drug, patients include addiction, which causes the need to increase the maintenance dose if long-term administration is necessary, as well as a poor combination with other anticonvulsants.

Price for Finlepsin retard in pharmacies

The price of Finlepsin retard 200 mg per package containing 50 tablets can be from 200 rubles, Finlepsin retard 400 mg - from 300 rubles.